Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Neurophth Closes $60 Million C Round for Ophthalmic Gene Therapies

publication date: Nov 24, 2021

Neurophth Therapeutics, a Wuhan-San Diego ophthalmic gene therapy company, closed a more-than $60 million Series C financing from China and international investors. Neurophth's lead candidate is the first AAV2 gene therapy IND application approved in China. The company said it would use the funds to advance its lead therapy for Leber hereditary optic neuropathy (LHON), a genetic blindness condition, outside of China after starting China trials in June 2021. The C round was led by CMG-SDIC Capital and Sequoia Capital China. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here


BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here


Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here